Loading...
The decision to initiate anti–tumor necrosis factor (anti-TNF) agents in inflammatory bowel disease (IBD) is typically made on clinical grounds, and after prior approval by insurance companies because of the high cost of these agents. Many patients require assistance from pharmaceutical companies because of the high cost.
Unfortunately, clinical trial data and experience indicate that about a third of patients are nonresponders. Better predictors of nonresponse are needed to save cost and reduce risks associated with unnecessary therapy.
In the current study, multiple cohorts of anti-TNF–naive patients with IBD were evaluated. Both biopsy tissue and blood were assessed for gene expression and other factors using special computational methods …